Proteomic markers of DNA repair and PI3K pathway activation predict response to the parp inhibitor BMN 673 in small cell lung cancer-letter

Clinical Cancer Research

Volumn 20, Issue 8, 2014, Pages 2236-

  Qiu, Haifeng ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BMN 673; OLAPARIB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; UNCLASSIFIED DRUG; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHTHALAZINE DERIVATIVE;

CANCER CELL CULTURE; DNA REPAIR; ENZYME ACTIVATION; HUMAN; LETTER; LUNG SMALL CELL CANCER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; FEMALE; LUNG NEOPLASMS; SMALL CELL LUNG CARCINOMA;

ANIMALS; DNA REPAIR; FEMALE; HUMANS; LUNG NEOPLASMS; PHTHALAZINES; POLY(ADP-RIBOSE) POLYMERASES; SMALL CELL LUNG CARCINOMA;

EID: 84898949108     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-2679     Document Type: Letter

References (5)

1. Cardnell RJ, Feng Y, Diao L, Fan YH, Masrorpour F, Wang J, et al. Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer. Clin Cancer Res 2013;19:6322-8.
2. Shen Y, Rehman FL, Feng Y, Boshuizen J, Bajrami I, Elliott R, et al.BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency. Clin Cancer Res 2013;19: 5003-15.
3. Minami D, Takigawa N, Takeda H, Takata M, Ochi N, Ichihara E, et al. Synergistic effect of olaparib with combination of cisplatin on PTEN-deficient lung cancer cells. Mol Cancer Res 2012;11: 140-8.
4. Dedes KJ, Wetterskog D, Mendes-Pereira AM, Natrajan R, Lambros MB, Geyer FC, et al. PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. Sci Transl Med 2010;2:53ra75.
5. Forster MD, Dedes KJ, Sandhu S, Frentzas S, Kristeleit R, Ashworth A, et al. Treatment with olaparib in a patient with PTENdeficient endometrioid endometrial cancer. Nat Rev Clin Oncol 2011;8:302-6.